SERA

-- Study Highlights Screening Efficiency and Potential Cost Savings in a Large Underserved Population -- SALT LAKE CITY, July 9, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information, today announced publication of a new subgroup analysis from the PRIME randomized controlled trial. The analysis demonstrated that PreTRM® Test-guided care in first-time pregnancies significantly improved neonatal outcomes, including a 22% reduction in neonatal intensive care unit (NICU) admissions.

SALT LAKE CITY, June 30, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Mark Capone will join its Board of Directors, effective July 1, 2026. Mr. Capone is a seasoned healthcare executive with more than 40 years of leadership experience across the diagnostics and life sciences sectors, including extensive service on private and public company boards and committees.

SALT LAKE CITY, June 24, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information, today announced its participation in a multi-institutional research program that was awarded up to $10.4 million by the Advanced Research Projects Agency for Health (ARPA-H) to develop a novel point-of-care diagnostic test designed to improve the safety of labor and delivery. The award, part of ARPA-H's Making Obstetrics Care Smart (MOCS) program, supports a collaboration led by researchers at the University of California San Diego (UC San Diego), alongside Sera Prognostics and Allegro MicroSystems.

--Aligns With Growing Focus on Early Identification and Management of Preterm Birth Risk-- SALT LAKE CITY, June 23, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information, today acknowledged recent legislative action in Illinois aimed at expanding access to evidence-based approaches for identifying and managing the risk of preterm birth among pregnant individuals. The legislation amends the Illinois Public Aid Code to require the state's medical assistance program (Medicaid) to provide coverage and reimbursement for prescribed proteomic blood tests that are used to identify and manage the risk of spontaneous preterm birth.

Sera Prognostics (SERA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

SALT LAKE CITY, June 1, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott has notified the Company of his intention to step down from its Board of Directors, effective June 4, 2026, and that he will not stand for re-election at the Company's upcoming Annual Meeting of Shareholders. Mr. Elliott has served on Sera's Board since March 2025, providing strategic guidance and leadership during a period of growth and development for the Company.

Sera Prognostics (SERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Sera Prognostics, Inc. (SERA) Q1 2026 Earnings Call Transcript

SALT LAKE CITY, May 6, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter ended March 31, 2026. Key First Quarter and Recent Highlights: Published Landmark PRIME Randomized Trial: Study in 5,018 women showing the PreTRM® test reduced early preterm births (–56%

SALT LAKE CITY, April 22, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report first quarter fiscal year 2026 financial results on Wednesday May 6, 2026, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m.